{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:08:29Z","timestamp":1791925709992,"version":"4.3.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CIHR Foundation Scheme grant","award":["148363"],"award-info":[{"award-number":["148363"]}]},{"name":"Canada Chair in Precursor Proteolysis","award":["950-231335"],"award-info":[{"award-number":["950-231335"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11883-022-01057-z","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T06:40:23Z","timestamp":1659076823000},"page":"821-830","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6503-9342","authenticated-orcid":false,"given":"Nabil G.","family":"Seidah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Gar\u00e7on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"issue":"3","key":"1057_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100(3):928\u201333.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1057_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154\u20136.","journal-title":"Nat Genet"},{"key":"1057_CR3","doi-asserted-by":"publisher","first-page":"100130","DOI":"10.1016\/j.jlr.2021.100130","volume":"62","author":"NG Seidah","year":"2021","unstructured":"Seidah NG. The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer. J Lipid Res. 2021;62:100130.","journal-title":"J Lipid Res"},{"issue":"5","key":"1057_CR4","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nrd3699","volume":"11","author":"NG Seidah","year":"2012","unstructured":"Seidah NG, Prat A. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012;11(5):367\u201383.","journal-title":"Nat Rev Drug Discov"},{"issue":"18","key":"1057_CR5","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1073\/pnas.0402133101","volume":"101","author":"KN Maxwell","year":"2004","unstructured":"Maxwell KN, Breslow JL. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A. 2004;101(18):7100\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"29","key":"1057_CR6","doi-asserted-by":"publisher","first-page":"20799","DOI":"10.1074\/jbc.C700095200","volume":"282","author":"MC McNutt","year":"2007","unstructured":"McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007;282(29):20799\u2013803.","journal-title":"J Biol Chem"},{"issue":"4","key":"1057_CR7","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1074\/jbc.M708098200","volume":"283","author":"S Poirier","year":"2008","unstructured":"Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem. 2008;283(4):2363\u201372.","journal-title":"J Biol Chem"},{"issue":"5","key":"1057_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nsmb1235","volume":"14","author":"D Cunningham","year":"2007","unstructured":"Cunningham D, Danley DE, Geoghegan KF, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol. 2007;14(5):413\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"1057_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.str.2007.04.004","volume":"15","author":"DE Piper","year":"2007","unstructured":"Piper DE, Jackson S, Liu Q, et al. The crystal structure of PCSK9 a regulator of plasma LDL-cholesterol. Structure. 2007;15(5):545\u201352.","journal-title":"Structure"},{"issue":"12","key":"1057_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1038\/embor.2011.205","volume":"12","author":"PL Surdo","year":"2011","unstructured":"Surdo PL, Bottomley MJ, Calzetta A, et al. Mechanistic implications for LDL receptor degradation from the PCSK9\/LDLR structure at neutral pH. EMBO Rep. 2011;12(12):1300\u20135.","journal-title":"EMBO Rep"},{"issue":"25","key":"1057_CR11","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282(25):18602\u201312.","journal-title":"J Biol Chem"},{"issue":"6","key":"1057_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","volume":"8","author":"N Nassoury","year":"2007","unstructured":"Nassoury N, Blasiole DA, Tebon OA, et al. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic. 2007;8(6):718\u201332.","journal-title":"Traffic"},{"key":"1057_CR13","doi-asserted-by":"crossref","unstructured":"Seidah NG, Prat A: The multifaceted biology of PCSK9. Endocr Rev 2021;43(3):558\u201382.","DOI":"10.1210\/endrev\/bnab035"},{"issue":"2","key":"1057_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1093\/eurheartj\/ehz566","volume":"41","author":"HD Jang","year":"2020","unstructured":"Jang HD, Lee SE, Yang J, et al. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin\/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin\/kexin type-9. Eur Heart J. 2020;41(2):239\u201352.","journal-title":"Eur Heart J"},{"key":"1057_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet. 2005;37:161.","journal-title":"Nat Genet"},{"issue":"15","key":"1057_CR16","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1073\/pnas.0501652102","volume":"102","author":"S Rashid","year":"2005","unstructured":"Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A. 2005;102(15):5374\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1057_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/hep.22354","volume":"48","author":"A Zaid","year":"2008","unstructured":"Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin\/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48(2):646\u201354.","journal-title":"Hepatology"},{"issue":"10","key":"1057_CR18","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","volume":"57","author":"J Mayne","year":"2011","unstructured":"Mayne J, Dewpura T, Raymond A, et al. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem. 2011;57(10):1415\u201323.","journal-title":"Clin Chem"},{"key":"1057_CR19","doi-asserted-by":"crossref","unstructured":"Lebeau PF, Wassef H, Byun JH, et al: The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. J Clin Invest\u00a02021;131(2):e128650.","DOI":"10.1172\/JCI128650"},{"issue":"3","key":"1057_CR20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1093\/cvr\/cvz003","volume":"115","author":"NG Seidah","year":"2019","unstructured":"Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Cardiovasc Res. 2019;115(3):510\u20138.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1057_CR21","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/CIRCRESAHA.118.313238","volume":"124","author":"RS Rosenson","year":"2019","unstructured":"Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. Circ Res. 2019;124(3):364\u201385.","journal-title":"Circ Res"},{"key":"1057_CR22","doi-asserted-by":"publisher","first-page":"115978","DOI":"10.1016\/j.taap.2022.115978","volume":"443","author":"D Lehoux","year":"2022","unstructured":"Lehoux D, Far AR, Kallend D, Wijngaard PLJ, Zerler B. Evaluation of the distribution and excretion of [(14)C]-inclisiran following single subcutaneous administration in cynomolgus monkeys. Toxicol Appl Pharmacol. 2022;443:115978.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1057_CR23","doi-asserted-by":"crossref","unstructured":"Gennemark P, Walter K, Clemmensen N, et al: An oral antisense oligonucleotide for PCSK9 inhibition. Sci Transl Med 2021;13(593):eabe9117","DOI":"10.1126\/scitranslmed.abe9117"},{"issue":"22","key":"1057_CR24","doi-asserted-by":"publisher","first-page":"16770","DOI":"10.1021\/acs.jmedchem.1c01599","volume":"64","author":"TJ Tucker","year":"2021","unstructured":"Tucker TJ, Embrey MW, Alleyne C, et al. A series of novel, highly potent, and orally bioavailable next-generation tricyclic peptide PCSK9 inhibitors. J Med Chem. 2021;64(22):16770\u2013800.","journal-title":"J Med Chem"},{"issue":"7859","key":"1057_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature. 2021;593(7859):429\u201334.","journal-title":"Nature"},{"issue":"6","key":"1057_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.2174\/0929867328666211027125245","volume":"29","author":"AA Momtazi-Borojeni","year":"2022","unstructured":"Momtazi-Borojeni AA, Pirro M, Xu S, Sahebkar A. PCSK9 inhibition-based therapeutic approaches: an immunotherapy perspective. Curr Med Chem. 2022;29(6):980\u201399.","journal-title":"Curr Med Chem"},{"issue":"2","key":"1057_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139\u201347.","journal-title":"JAMA Cardiol"},{"issue":"8","key":"1057_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","volume":"7","author":"KK Ray","year":"2019","unstructured":"Ray KK, Colhoun HM, Szarek M, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618\u201328.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1057_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4269\/ajtmh.1967.16.339","volume":"16","author":"WE Brandt","year":"1967","unstructured":"Brandt WE, Buescher EL, Hetrick FM. Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg. 1967;16(3):339\u201347.","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"1057_CR30","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/fca-2020-0150","volume":"17","author":"J Brandts","year":"2021","unstructured":"Brandts J, Ray KK. Clinical implications and outcomes of the ORION phase III trials. Future Cardiol. 2021;17(5):769\u201377.","journal-title":"Future Cardiol"},{"issue":"5","key":"1057_CR31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/S2213-8587(22)00043-2","volume":"10","author":"P Ostadal","year":"2022","unstructured":"Ostadal P, Steg PG, Poulouin Y, et al. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022;10(5):330\u201340.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1057_CR32","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Kataoka Y, Nissen SE, et al: Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction. JACC Cardiovasc Imaging 2022;15(7):1308\u201321.","DOI":"10.1016\/j.jcmg.2022.03.002"},{"key":"1057_CR33","doi-asserted-by":"publisher","unstructured":"Desita SR, Hariftyani AS, Jannah AR, Setyobudi AK, Oktaviono YH: PCSK9 and LRP6: potential combination targets to prevent and reduce atherosclerosis. J Basic Clin Physiol Pharmacol 2022.\u00a0 https:\/\/doi.org\/10.1515\/jbcpp-2021-0291","DOI":"10.1515\/jbcpp-2021-0291"},{"issue":"13","key":"1057_CR34","first-page":"2525","volume":"117","author":"P Libby","year":"2021","unstructured":"Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovasc Res. 2021;117(13):2525\u201336.","journal-title":"Cardiovasc Res"},{"key":"1057_CR35","doi-asserted-by":"publisher","unstructured":"Liu A, Frosteg\u00e5rd J: PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque. J Intern Med 2018 (in press): https:\/\/doi.org\/10.1111\/joim.12758.","DOI":"10.1111\/joim.12758"},{"issue":"1","key":"1057_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","volume":"18","author":"J Frosteg\u00e5rd","year":"2022","unstructured":"Frosteg\u00e5rd J. The role of PCSK9 in inflammation, immunity, and autoimmune diseases. Expert Rev Clin Immunol. 2022;18(1):67\u201374.","journal-title":"Expert Rev Clin Immunol"},{"issue":"4","key":"1057_CR37","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3892\/ijmm.2012.1072","volume":"30","author":"Z Tang","year":"2012","unstructured":"Tang Z, Jiang L, Peng J, et al. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kappaB activation in THP-1-derived macrophages. Int J Mol Med. 2012;30(4):931\u20138.","journal-title":"Int J Mol Med"},{"key":"1057_CR38","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1093\/cvr\/cvv178","volume":"107","author":"Z Ding","year":"2015","unstructured":"Ding Z, Liu S, Wang X, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res. 2015;107:556\u201367.","journal-title":"Cardiovasc Res"},{"issue":"10","key":"1057_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1161\/CIRCRESAHA.118.312804","volume":"123","author":"K Kim","year":"2018","unstructured":"Kim K, Shim D, Lee JS, et al. Transcriptome analysis reveals nonfoamy rather than foamy plaque macrophages are proinflammatory in atherosclerotic murine models. Circ Res. 2018;123(10):1127\u201342.","journal-title":"Circ Res"},{"key":"1057_CR40","doi-asserted-by":"publisher","first-page":"112460","DOI":"10.1016\/j.biopha.2021.112460","volume":"145","author":"P Marques","year":"2022","unstructured":"Marques P, Domingo E, Rubio A, et al. Beneficial effects of PCSK9 inhibition with alirocumab in familial hypercholesterolemia involve modulation of new immune players. Biomed Pharmacother. 2022;145:112460.","journal-title":"Biomed Pharmacother"},{"issue":"52","key":"1057_CR41","doi-asserted-by":"publisher","first-page":"43492","DOI":"10.1074\/jbc.M112.394023","volume":"287","author":"YG Saavedra","year":"2012","unstructured":"Saavedra YG, Day R, Seidah NG. The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 is needed for the extracellular low density lipoprotein receptor (LDLR) degradation pathway. J Biol Chem. 2012;287(52):43492\u2013501.","journal-title":"J Biol Chem"},{"issue":"37","key":"1057_CR42","doi-asserted-by":"publisher","first-page":"14604","DOI":"10.1073\/pnas.0703402104","volume":"104","author":"EN Hampton","year":"2007","unstructured":"Hampton EN, Knuth MW, Li J, Harris JL, Lesley SA, Spraggon G. The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain. Proc Natl Acad Sci U S A. 2007;104(37):14604\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1057_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.clim.2009.07.013","volume":"133","author":"M Filkov\u00e1","year":"2009","unstructured":"Filkov\u00e1 M, Haluz\u00edk M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: Implications for various human pathologies. Clin Immunol. 2009;133(2):157\u201370.","journal-title":"Clin Immunol"},{"issue":"19","key":"1057_CR44","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/j.jacc.2011.11.064","volume":"59","author":"M Melone","year":"2012","unstructured":"Melone M, Wilsie L, Palyha O, Strack A, Rashid S. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin\/kexin type 9. J Am Coll Cardiol. 2012;59(19):1697\u2013705.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1057_CR45","doi-asserted-by":"publisher","first-page":"e64145","DOI":"10.1371\/journal.pone.0064145","volume":"8","author":"M Canuel","year":"2013","unstructured":"Canuel M, Sun X, Asselin MC, Paramithiotis E, Prat A, Seidah NG. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1). PLoS ONE. 2013;8(5):e64145.","journal-title":"PLoS ONE"},{"issue":"12","key":"1057_CR46","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","volume":"35","author":"A Demers","year":"2015","unstructured":"Demers A, Samani S, Lauzier B, et al. PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver. Arterioscler Thromb Vasc Biol. 2015;35(12):2517\u201325.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"42","key":"1057_CR47","doi-asserted-by":"publisher","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier S, Mayer G, Poupon V, et al. Dissection of the endogenous cellular pathways of PCSK9-induced LDLR degradation: evidence for an intracellular route. J Biol Chem. 2009;284(42):28856\u201364.","journal-title":"J Biol Chem"},{"key":"1057_CR48","doi-asserted-by":"publisher","unstructured":"\u2022 Byun JH, Lebeau PF, Platko K, et al: Inhibitory antibodies against PCSK9 reduce surface CD36 and mitigate diet-induced renal lipotoxicity. Kidney360 2022 (in press): https:\/\/doi.org\/10.34067\/KID.0007022021.(This study suggests that the binding domains that PCSK9 uses to interact and degrade both the LDLR and CD36 are distinct, and that CD36 may rather bind the CHRD of PCSK9\u2022)","DOI":"10.34067\/KID.0007022021"},{"issue":"6","key":"1057_CR49","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","volume":"1","author":"PF Lebeau","year":"2019","unstructured":"Lebeau PF, Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 2019;1(6):418\u201329.","journal-title":"JHEP Rep"},{"issue":"16","key":"1057_CR50","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319.","journal-title":"N Engl J Med"},{"issue":"1","key":"1057_CR51","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/BJ20130930","volume":"457","author":"TB Strom","year":"2014","unstructured":"Strom TB, Tveten K, Leren TP. PCSK9 acts as a chaperone for the LDL receptor in the endoplasmic reticulum. Biochem J. 2014;457(1):99\u2013105.","journal-title":"Biochem J"},{"issue":"6","key":"1057_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157230","volume":"11","author":"S Poirier","year":"2016","unstructured":"Poirier S, Hamouda HA, Villeneuve L, Demers A, Mayer G. Trafficking dynamics of PCSK9-induced LDLR degradation: focus on human PCSK9 mutations and C-terminal domain. PLoS ONE. 2016;11(6): e0157230.","journal-title":"PLoS ONE"},{"issue":"40","key":"1057_CR53","doi-asserted-by":"publisher","first-page":"33745","DOI":"10.1074\/jbc.M112.399725","volume":"287","author":"S Benjannet","year":"2012","unstructured":"Benjannet S, Hamelin J, Chretien M, Seidah NG. Loss- and gain-of-function PCSK9 variants: clevage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem. 2012;287(40):33745\u201355.","journal-title":"J Biol Chem"},{"issue":"19","key":"1057_CR54","doi-asserted-by":"publisher","first-page":"7329","DOI":"10.1074\/jbc.RA117.001049","volume":"293","author":"P Lebeau","year":"2018","unstructured":"Lebeau P, Platko K, Al-Hashimi AA, et al. Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. J Biol Chem. 2018;293(19):7329\u201343.","journal-title":"J Biol Chem"},{"issue":"10","key":"1057_CR55","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1016\/j.celrep.2015.11.006","volume":"13","author":"S Poirier","year":"2015","unstructured":"Poirier S, Mamarbachi M, Chen WT, Lee AS, Mayer G. GRP94 regulates circulating cholesterol levels through blockade of PCSK9-induced LDLR degradation. Cell Rep. 2015;13(10):2064\u201371.","journal-title":"Cell Rep"},{"issue":"7","key":"1057_CR56","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S0092-8674(00)81304-5","volume":"85","author":"J Sakai","year":"1996","unstructured":"Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. Cell. 1996;85(7):1037\u201346.","journal-title":"Cell"},{"issue":"7","key":"1057_CR57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1515\/BC.2006.110","volume":"387","author":"NG Seidah","year":"2006","unstructured":"Seidah NG, Khatib AM, Prat A. The proprotein convertases and their implication in sterol and\/or lipid metabolism. Biol Chem. 2006;387(7):871\u20137.","journal-title":"Biol Chem"},{"issue":"8","key":"1057_CR58","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","volume":"24","author":"G Dubuc","year":"2004","unstructured":"Dubuc G, Chamberland A, Wassef H, et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2004;24(8):1454\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"1057_CR59","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.cmet.2005.04.006","volume":"1","author":"AD Attie","year":"2005","unstructured":"Attie AD, Seidah NG. Dual regulation of the LDL receptor\u2013some clarity and new questions. Cell Metab. 2005;1(5):290\u20132.","journal-title":"Cell Metab"},{"issue":"2","key":"1057_CR60","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","volume":"49","author":"HJ Jeong","year":"2008","unstructured":"Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49(2):399\u2013409.","journal-title":"J Lipid Res"},{"issue":"1","key":"1057_CR61","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41467-022-28240-9","volume":"13","author":"PF Lebeau","year":"2022","unstructured":"\u2022 Lebeau PF, Byun JH, Platko K, et al. Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance. Nat Commun. 2022;13(1):770. (Findings from this study suggest that caffeine and some of its xanthine derivatives increase hepatic ER Ca2+ levels, and effectively block de novo synthesis of PCSK9, and reduce its circulating levels in vitro, in vivo, and in healthy volunteers\u2022)","journal-title":"Nat Commun"},{"issue":"1","key":"1057_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1124\/pr.116.012989","volume":"69","author":"NG Seidah","year":"2017","unstructured":"Seidah NG, Abifadel M, Prost S, Boileau C, Prat A. The proprotein convertases in hypercholesterolemia and cardiovascular diseases: emphasis on proprotein convertase subtilisin\/kexin 9. Pharmacol Rev. 2017;69(1):33\u201352.","journal-title":"Pharmacol Rev"},{"issue":"166","key":"1057_CR63","doi-asserted-by":"publisher","first-page":"166ra161","DOI":"10.1126\/scitranslmed.3004853","volume":"5","author":"RH Al-Mashhadi","year":"2013","unstructured":"Al-Mashhadi RH, Sorensen CB, Kragh PM, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013;5(166):166ra161.","journal-title":"Sci Transl Med"},{"issue":"7","key":"1057_CR64","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1161\/ATVBAHA.110.204040","volume":"30","author":"B Herbert","year":"2010","unstructured":"Herbert B, Patel D, Waddington SN, et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol. 2010;30(7):1333\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1057_CR65","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1161\/ATVBAHA.114.303617","volume":"35","author":"M Roche-Molina","year":"2015","unstructured":"Roche-Molina M, Sanz-Rosa D, Cruz FM, et al. Induction of sustained hypercholesterolemia by single adeno-associated virus-mediated gene transfer of mutant hPCSK9. Arterioscler Thromb Vasc Biol. 2015;35(1):50\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1057_CR66","doi-asserted-by":"publisher","first-page":"e0173975","DOI":"10.1371\/journal.pone.0173975","volume":"12","author":"M Peled","year":"2017","unstructured":"Peled M, Nishi H, Weinstock A, et al. A wild-type mouse-based model for the regression of inflammation in atherosclerosis. PLoS ONE. 2017;12(3):e0173975.","journal-title":"PLoS ONE"},{"key":"1057_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/978-1-0716-1924-7_27","volume":"2419","author":"MM Bj\u00f8rklund","year":"2022","unstructured":"Bj\u00f8rklund MM, Bernal JA, Bentzon JF. Atherosclerosis induced by adeno-associated virus encoding gain-of-function PCSK9. Methods Mol Biol. 2022;2419:461\u201373.","journal-title":"Methods Mol Biol"},{"issue":"7","key":"1057_CR68","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3390\/v13071229","volume":"13","author":"NG Seidah","year":"2021","unstructured":"Seidah NG, Pasquato A, Andr\u00e9o U. How do enveloped viruses exploit the secretory proprotein convertases to regulate infectivity and spread? Viruses. 2021;13(7):1229.","journal-title":"Viruses"},{"issue":"4","key":"1057_CR69","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.jhep.2014.11.016","volume":"62","author":"SH Bridge","year":"2015","unstructured":"Bridge SH, Sheridan DA, Felmlee DJ, et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism. J Hepatol. 2015;62(4):763\u201370.","journal-title":"J Hepatol"},{"issue":"38","key":"1057_CR70","doi-asserted-by":"publisher","first-page":"23385","DOI":"10.1074\/jbc.M115.642991","volume":"290","author":"QT Le","year":"2015","unstructured":"Le QT, Blanchet M, Seidah NG, Labonte P. Plasma membrane CD81 complexes with PCSK9 and LDLR and its levels are reduced by PCSK9. J Biol Chem. 2015;290(38):23385\u2013400.","journal-title":"J Biol Chem"},{"issue":"12","key":"1057_CR71","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/jcmm.13273","volume":"21","author":"M Pirro","year":"2017","unstructured":"Pirro M, Bianconi V, Francisci D, et al. Hepatitis C virus and proprotein convertase subtilisin\/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J Cell Mol Med. 2017;21(12):3150\u201361.","journal-title":"J Cell Mol Med"},{"issue":"19","key":"1057_CR72","doi-asserted-by":"publisher","first-page":"e009996","DOI":"10.1161\/JAHA.118.009996","volume":"7","author":"TM Leucker","year":"2018","unstructured":"Leucker TM, Weiss RG, Sch\u00e4r M, et al. Coronary endothelial dysfunction is associated with elevated serum PCSK9 levels in people with HIV Independent of low-density lipoprotein cholesterol. J Am Heart Assoc. 2018;7(19):e009996.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"1057_CR73","doi-asserted-by":"publisher","first-page":"e016263","DOI":"10.1161\/JAHA.120.016263","volume":"9","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Gerstenblith G, Sch\u00e4r M, et al. Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9(14):e016263.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"1057_CR74","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2020.06.015","volume":"32","author":"XJ Zhang","year":"2020","unstructured":"Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metab. 2020;32(2):176-187.e4.","journal-title":"Cell Metab"},{"issue":"1159","key":"1057_CR75","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/postgradmedj-2020-139172","volume":"98","author":"R Pal","year":"2022","unstructured":"Pal R, Banerjee M, Yadav U, Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: an updated systematic review and meta-analysis. Postgrad Med J. 2022;98(1159):354\u20139.","journal-title":"Postgrad Med J"},{"issue":"8","key":"1057_CR76","doi-asserted-by":"publisher","first-page":"e0012822","DOI":"10.1128\/jvi.00128-22","volume":"96","author":"R Essalmani","year":"2022","unstructured":"Essalmani R, Jain J, Susan-Resiga D, et al. Distinctive roles of furin and TMPRSS2 in SARS-CoV-2 infectivity. J Virol. 2022;96(8):e0012822.","journal-title":"J Virol"},{"issue":"4","key":"1057_CR77","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cid\/civ949","volume":"62","author":"J Whitehorn","year":"2016","unstructured":"Whitehorn J, Nguyen CVV, Khanh LP, et al. Lovastatin for the treatment of adult patients with dengue: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2016;62(4):468\u201376.","journal-title":"Clin Infect Dis"},{"issue":"7446","key":"1057_CR78","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nature12060","volume":"496","author":"S Bhatt","year":"2013","unstructured":"Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504\u20137.","journal-title":"Nature"},{"issue":"10","key":"1057_CR79","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1172\/JCI137536","volume":"130","author":"ES Gan","year":"2020","unstructured":"Gan ES, Tan HC, Le DHT, et al. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J Clin Invest. 2020;130(10):5223\u201334.","journal-title":"J Clin Invest"},{"issue":"3","key":"1057_CR80","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","volume":"89","author":"MS Brown","year":"1997","unstructured":"Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997;89(3):331\u201340.","journal-title":"Cell"},{"issue":"4","key":"1057_CR81","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/ATVBAHA.110.220988","volume":"31","author":"A Roubtsova","year":"2011","unstructured":"Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin\/kexin 9 (PCSK9) Regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31(4):785\u201391.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"1057_CR82","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/toxsci\/kfu093","volume":"140","author":"TR Gelzleichter","year":"2014","unstructured":"Gelzleichter TR, Halpern W, Erwin R, et al. Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function. Toxicol Sci. 2014;140(2):470\u201380.","journal-title":"Toxicol Sci"},{"issue":"7839","key":"1057_CR83","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"\u2022\u2022 Liu X, Bao X, Hu M, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588(7839):693\u20138. (This seminal study suggests that the use of PCSK9i not only reduced LDLc levels but also enhanced the efficacy of cancer immune therapy targeted to the checkpoint protein PD-1\u2022\u2022)","journal-title":"Nature"},{"issue":"4","key":"1057_CR84","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s13238-021-00821-2","volume":"12","author":"J Yuan","year":"2021","unstructured":"Yuan J, Cai T, Zheng X, et al. Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling. Protein Cell. 2021;12(4):240\u201360.","journal-title":"Protein Cell"},{"issue":"3","key":"1057_CR85","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jacl.2017.04.001","volume":"11","author":"A Gangloff","year":"2017","unstructured":"Gangloff A, Calon F, Seidah NG. Can iPCSK9-induced hypocholesterolemia starve cancer cells? J Clin Lipidol. 2017;11(3):600\u20131.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"1057_CR86","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s00210-022-02200-y","volume":"395","author":"H Sun","year":"2022","unstructured":"Sun H, Meng W, Zhu J, Wang L. Antitumor activity and molecular mechanism of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(6):643\u201358.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"9","key":"1057_CR87","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1161\/ATVBAHA.120.314194","volume":"40","author":"D Gar\u00e7on","year":"2020","unstructured":"Gar\u00e7on D, Moreau F, Ayer A, et al. Circulating rather than intestinal PCSK9 (proprotein convertase subtilisin kexin type 9) regulates postprandial lipemia in mice. Arterioscler Thromb Vasc Biol. 2020;40(9):2084\u201394.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1057_CR88","doi-asserted-by":"publisher","first-page":"158968","DOI":"10.1016\/j.bbalip.2021.158968","volume":"1866","author":"ML Peyot","year":"2021","unstructured":"\u2022 Peyot ML, Roubtsova A, Lussier R, et al. Substantial PCSK9 inactivation in \u03b2-cells does not modify glucose homeostasis or insulin secretion in mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2021;1866(8):158968. (This study revealed that in mouse the deletion of PCSK9 expression from whole body or in pancreatic \u03b2-cells knockout mice does not affect insulin levels or result in any toxic effects on \u03b2-cell function and glucose homeostasis. This conclusion agrees with observations from clinical trials of the lack of effects of PCSK9 mAbs on diabetes risk\u2022)","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"9","key":"1057_CR89","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/kjm2.12225","volume":"36","author":"L Lei","year":"2020","unstructured":"Lei L, Li X, Yuan YJ, et al. Inhibition of proprotein convertase subtilisin\/kexin type 9 attenuates 2,4,6-trinitrobenzenesulfonic acid-induced colitis via repressing Toll-like receptor 4\/nuclear factor-kappa B. Kaohsiung J Med Sci. 2020;36(9):705\u201311.","journal-title":"Kaohsiung J Med Sci"},{"key":"1057_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-981-13-9367-9_2","volume":"1172","author":"J Jiang","year":"2019","unstructured":"Jiang J, Natarajan K, Margulies DH. MHC Molecules, T cell receptors, natural killer cell receptors, and viral immunoevasins-key elements of adaptive and innate immunity. Adv Exp Med Biol. 2019;1172:21\u201362.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"1057_CR91","doi-asserted-by":"crossref","first-page":"897","DOI":"10.4049\/jimmunol.161.2.897","volume":"161","author":"W B\u00f6hm","year":"1998","unstructured":"B\u00f6hm W, Thoma S, Leith\u00e4user F, M\u00f6ller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol. 1998;161(2):897\u2013908.","journal-title":"J Immunol"},{"issue":"12","key":"1057_CR92","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1016\/j.stemcr.2021.10.004","volume":"16","author":"M Roudaut","year":"2021","unstructured":"Roudaut M, Idriss S, Caillaud A, et al. PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. Stem Cell Reports. 2021;16(12):2958\u201372.","journal-title":"Stem Cell Reports"},{"issue":"10","key":"1057_CR93","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.3390\/ijms19103090","volume":"19","author":"P Dlugosz","year":"2018","unstructured":"Dlugosz P, Nimpf J. The reelin receptors apolipoprotein E receptor 2 (ApoER2) and VLDL receptor. Int J Mol Sci. 2018;19(10):3090.","journal-title":"Int J Mol Sci"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-022-01057-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-022-01057-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:26:58Z","timestamp":1744187218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-022-01057-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1057"],"URL":"https:\/\/doi.org\/10.1007\/s11883-022-01057-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,29]]},"assertion":[{"value":"5 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a review article dealing with PCSK9 and its various functions. It refers to previous publications on human and animal studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}